| scholarly article | Q13442814 |
| P2093 | author name string | Massimo Trucco | |
| Nick Giannoukakis | |||
| Yesica Garciafigueroa | |||
| Brett Eugene Phillips | |||
| P2860 | cites work | Characterization of Dendritic Cells that Induce Tolerance and T Regulatory 1 Cell Differentiation In Vivo | Q73407790 |
| Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes | Q74595801 | ||
| Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? | Q74675085 | ||
| Glucocorticoids affect human dendritic cell differentiation and maturation | Q77823491 | ||
| Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 | Q78804319 | ||
| Inducing and expanding regulatory T cell populations by foreign antigen | Q81392563 | ||
| Mechanical interactions between dendritic cells and T cells correlate with T cell responsiveness | Q84217956 | ||
| Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials | Q21131223 | ||
| Insulin and insulin resistance. | Q24532776 | ||
| Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer | Q24681630 | ||
| Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man | Q26776126 | ||
| Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage | Q26778646 | ||
| Regulation of Dendritic Cell Function by Vitamin D | Q26781521 | ||
| Regulatory dendritic cells for immunotherapy in immunologic diseases | Q26866216 | ||
| Treg functional stability and its responsiveness to the microenvironment | Q27008946 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis | Q28082878 | ||
| Crohn's disease | Q28273481 | ||
| Metabolic control of dendritic cell activation and function: recent advances and clinical implications | Q28385947 | ||
| Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies | Q28596281 | ||
| Dendritic cells: specialized and regulated antigen processing machines | Q29617085 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| Retinoic acid imprints gut-homing specificity on T cells | Q29619126 | ||
| The role of dendritic cells in autoimmunity | Q30047565 | ||
| Rheumatoid arthritis. | Q30244019 | ||
| Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation | Q33344421 | ||
| Regulatory activity of autocrine IL-10 on dendritic cell functions | Q33938563 | ||
| Dendritic-cell trafficking to lymph nodes through lymphatic vessels | Q33989067 | ||
| The nuclear factor NF-kappaB pathway in inflammation | Q34114512 | ||
| Cross-presentation, dendritic cells, tolerance and immunity | Q34178099 | ||
| Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. | Q34193317 | ||
| Dendritic cells in transplantation--friend or foe? | Q34241103 | ||
| Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming | Q34323795 | ||
| Human regulatory T cells in autoimmune diseases | Q34384366 | ||
| Crohn's disease: a review of treatment options and current research | Q34390714 | ||
| Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells | Q34540737 | ||
| In vivo instruction of suppressor commitment in naive T cells | Q34548023 | ||
| How tolerogenic dendritic cells induce regulatory T cells | Q34631825 | ||
| Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts | Q34635933 | ||
| Epidemiology and genetics of rheumatoid arthritis | Q34731244 | ||
| Immature, but not inactive: the tolerogenic function of immature dendritic cells | Q34842360 | ||
| High prevalence of vitamin A deficiency in Crohn's disease patients according to serum retinol levels and the relative dose-response test | Q35045798 | ||
| Advances in the medical treatment of rheumatoid arthritis | Q35102474 | ||
| Vitamin D and the immune system | Q35194610 | ||
| Tolerogenic dendritic cells and their role in transplantation. | Q35341379 | ||
| Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review | Q35979221 | ||
| Regulation of immunity by self-reactive T cells | Q36148406 | ||
| The role of retinoic acid in tolerance and immunity | Q36162881 | ||
| Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity | Q36199422 | ||
| Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity | Q36202057 | ||
| CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells | Q36228572 | ||
| Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 | ||
| Imbalance of regulatory T cells in human autoimmune diseases | Q36395703 | ||
| Dendritic cells in a mature age. | Q36475977 | ||
| Vitamin D and rheumatoid arthritis | Q36515194 | ||
| Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? | Q36782375 | ||
| Tolerogenic dendritic cells and regulatory T cells: a two-way relationship | Q36788761 | ||
| Tolerogenic dendritic cells and the quest for transplant tolerance | Q36879029 | ||
| Allogeneic islet transplantation | Q36981652 | ||
| Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus. | Q37190971 | ||
| Mechanisms and consequences of dendritic cell migration | Q37272221 | ||
| Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells | Q37286777 | ||
| Tolerogenic dendritic cells for autoimmune disease and transplantation | Q37331113 | ||
| Dendritic cell migration to peripheral lymph nodes | Q37334046 | ||
| Inflammatory signals in dendritic cell activation and the induction of adaptive immunity | Q37361473 | ||
| T-cell activation by dendritic cells in the lymph node: lessons from the movies | Q37378582 | ||
| Role of regulatory T-cells in autoimmunity | Q37411718 | ||
| Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice | Q37490637 | ||
| Biology of lung dendritic cells at the origin of asthma | Q37600198 | ||
| Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis | Q37604510 | ||
| The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights | Q37732574 | ||
| Role of dendritic cells in the induction of regulatory T cells | Q37895356 | ||
| Stability of regulatory T-cell lineage. | Q37961172 | ||
| Human tolerogenic DC-10: perspectives for clinical applications. | Q38078109 | ||
| Human dendritic cell subsets | Q38101992 | ||
| Tolerogenic dendritic cells as a therapy for treating lupus | Q38115047 | ||
| Regulatory T cells as immunotherapy | Q38191610 | ||
| Vitamin A and dendritic cell differentiation | Q38213059 | ||
| TREG-cell therapies for autoimmune rheumatic diseases. | Q38224804 | ||
| Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions | Q38275584 | ||
| Antigen Presentation by MHC-Dressed Cells | Q38324534 | ||
| Clinical pancreatic islet transplantation. | Q39005220 | ||
| Dendritic cell migration in health and disease | Q39021691 | ||
| Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel s | Q39436182 | ||
| Immunomodulatory effects of Vitamin D in multiple sclerosis | Q39868289 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. | Q40989701 | ||
| Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. | Q41180997 | ||
| Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis | Q41283113 | ||
| Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor | Q41494516 | ||
| Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes | Q42241451 | ||
| Comparative study of clinical grade human tolerogenic dendritic cells | Q42836981 | ||
| Dendritic cell survival and maturation are regulated by different signaling pathways. | Q42971737 | ||
| Regulatory T-cell therapy: is it ready for the clinic? | Q43513695 | ||
| Developmental plasticity of murine and human Foxp3(+) regulatory T cells | Q43534335 | ||
| 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. | Q46129067 | ||
| Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation | Q46152226 | ||
| Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study. | Q50438028 | ||
| Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients | Q57221897 | ||
| Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis | Q57330540 | ||
| Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10 | Q59640223 | ||
| Vitamin D and multiple sclerosis | Q59655772 | ||
| P921 | main subject | dendritic cell | Q506253 |
| autoimmune disease | Q8084905 | ||
| P304 | page(s) | 1279 | |
| P577 | publication date | 2017-10-12 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease | |
| P478 | volume | 8 |
| Q64106840 | 1,25-Dihydroxyvitamin D Restrains CD4 T Cell Priming Ability of CD11c Dendritic Cells by Upregulating Expression of CD31 |
| Q55265513 | Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. |
| Q59754901 | Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy? |
| Q104264527 | Cross talk between human regulatory T cells and antigen presenting cells: Lessons for clinical applications |
| Q92121412 | Dendritic cells mediate the anti-inflammatory action of omega-3 long-chain polyunsaturated fatty acids in experimental autoimmune uveitis |
| Q64116567 | Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model |
| Q96951726 | Engineering immunomodulatory biomaterials for type 1 diabetes |
| Q64241648 | Ethyl Pyruvate Induces Tolerogenic Dendritic Cells |
| Q53818876 | Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation. |
| Q98906910 | Human immunology and immunotherapy: main achievements and challenges |
| Q64228779 | Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies |
| Q52678835 | Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. |
| Q64068295 | Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial |
| Q64084407 | Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis |
| Q55013923 | Interleukin-10-Producing DC-10 Is a Unique Tool to Promote Tolerance Via Antigen-Specific T Regulatory Type 1 Cells. |
| Q99212132 | Mir-27a-3p attenuates bronchiolitis obliterans in vivo via the regulation of dendritic cells' maturation and the suppression of myofibroblasts' differentiation |
| Q92222884 | Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy |
| Q64268733 | Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? |
| Q89736141 | Regulatory Dendritic Cells Induced by K313 Display Anti-Inflammatory Properties and Ameliorate Experimental Autoimmune Encephalitis in Mice |
| Q92243921 | STAT3 Activation in Combination with NF-KappaB Inhibition Induces Tolerogenic Dendritic Cells with High Therapeutic Potential to Attenuate Collagen-Induced Arthritis |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
| Q61798675 | Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy |
| Q99726047 | Treg Enhancing Therapies to Treat Autoimmune Diseases |
Search more.